Document Detail


Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.
MedLine Citation:
PMID:  2539290     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly, a clinical study demonstrated that enalapril reduces mortality when added to established therapy in patients with severe congestive heart failure (NYHA class IV) refractory to digitalis, diuretics and other vasodilators. Thus, ACE inhibitors such as enalapril offer a significant advance in the treatment of congestive heart failure. Because these drugs improve symptoms in patients with classes II to IV failure, and reduce mortality in patients with severe heart failure, they should be considered as first choice adjuvant therapy when a vasodilator is needed in addition to conventional treatment with digitalis and diuretics.
Authors:
P A Todd; K L Goa
Publication Detail:
Type:  Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  37     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-05-15     Completed Date:  1989-05-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  141-61     Citation Subset:  IM    
Affiliation:
ADIS Drug Information Services, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Double-Blind Method
Enalapril* / administration & dosage,  adverse effects,  pharmacology,  therapeutic use
Heart Failure / drug therapy*
Humans
Random Allocation
Chemical
Reg. No./Substance:
75847-73-3/Enalapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The familial carcinoma burden and indications for subcutaneous mastectomy
Next Document:  Marked blood pressure fluctuations during narcoleptic attacks alternating with abnormal wakefulness:...